Latest news for Argentex Group (OTC:AGXTF) Stock

Argentex Group PLC is a United Kingdom-based foreign exchange service provider. It operates as a Riskless Principal broker for non-speculative, spot, and forward foreign exchange and structured financial derivative contracts. The company's client base includes institutions and corporates in a range of industries.

Argentex Group PLC

On Friday, October 11th, U.S. markets closed in green, fueled by strong performances in financial stocks after major banks reported robust quarterly results. JPMorgan, Wells Fargo, and BlackRock surpassed profit expectations, boosting the S&amp;P Financials index. This positive start to earnings season and encouraging inflation data raised expectations for a potential Federal Reserve rate cut in November.
According to economic data, in September, U.S. core producer prices rose by 0.2% from the previous month, slightly lower than the 0.3% increase recorded in August.
Most S&amp;P 500 sectors closed higher on Friday, led by financials, real estate, and industrials, while consumer discretionary and information technology stocks ended lower.
The Dow Jones Industrial Average was up 0.97% and closed at 42,863.86. The S&amp;P 500 ended the day higher by 0.61% at 5,815.03, and the Nasdaq Composite rose 0.33%, finishing the session at 18,342.94.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Asia Markets Today
<ul>
<li>Japan markets closed for the National Sports Day holiday.</li>
<li>On Monday, Australia&#8217;s S&amp;P/ASX 200 gained 0.47% and ended the day at 8,252.80, led by gains in the Gold, Materials and Metals &amp; Mining sectors.</li>
<li>India&#8217;s Nifty 50 traded higher by 0.69% at 25,135.45, and the Nifty 500 was up 0.51% at 23,730.75.</li>
<li>China&#8217;s Shanghai Composite rose 2.07% to close at 3,284.32, and the Shenzhen CSI 300 gained 1.91%, finishing the day at 3,961.34.</li>
<li>Hong Kong&#8217;s Hang Seng slid 0.75% and closed the session at 21,092.87.</li>
<li>Stock markets held below last month&#8217;s highs as China&#8217;s stimulus promises failed to impress investors. U.S. and European shares edged up, while China&#8217;s yuan weakened and oil prices fell due to demand concerns.</li>
</ul>
Eurozone at 06:00 AM ET
<ul>
<li>The European STOXX 50 index was up 0.01%.</li>
<li>Germany&#8217;s DAX gained 0.32%.</li>
<li>France&#8217;s CAC fell 0.35%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.07%.</li>
</ul>
Commodities at 06:00 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 2.70% at $73.50/bbl, and Brent was down 2.57% at $77.02/bbl.</li>
<li>Oil prices dropped, erasing last week&#8217;s gains, as China&#8217;s vague stimulus plans failed to inspire confidence and deflationary pressures worsened. Market concerns over potential Israeli attacks on Iranian oil infrastructure persisted.</li>
<li>Natural Gas was down 1.98% at $2.580.</li>
<li>Gold was trading lower by 0.03% at $2,675.40, Silver slid 0.56% to $31.578, and Copper declined 1.37% to $4.4318.</li>
</ul>
U.S. Futures at 06:00 AM ET
Dow futures were down 0.08%, S&amp;P 500 futures rose 0.12%, and Nasdaq 100 Futures gained 017%.
Forex at 06:00 AM ET
The U.S. dollar index rose 0.15% to 103.04, the USD/JPY rose 0.20% to 149.43, and the USD/AUD gained 0.23% to 1.4877.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

News

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Gains, Europe Markets Mixed; Crude Cools Off On Global Demand Worries While Dollar Strengthens - Global Markets Today While US Slept

U.S. auto safety regulator National Highway Traffic Safety Administration (NHTSA) said on Monday that it is opening a preliminary evaluation into Ford Motor Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) 2019 model year Flex vehicles over allegations of rearview camera failure.
What Happened: The probe covers an estimated 35,950 Flex vehicles. 
The NHTSA opened the investigation after it became aware of 23 allegations of rear-view camera failure in model year 2019 Flex vehicles. 
The complainants alleged black, distorted, or inverted rearview camera images when reversing, the regulator said. An upside-down image, the NHTSA said, will risk the driver.
The preliminary evaluation is aimed at determining the severity of the potential problem, the regulator added. 
Ford discontinued the production of the Flex SUV in late 2019. 
Why It Matters: SUVs comprise a majority of Ford&#8217;s <a href="https://www.benzinga.com/news/24/10/41140072/ford-reduces-costs-of-hands-free-driving-technology-bluecruise-in-us-now-also-available-as-a-one-tim">vehicle sales in the U.S. </a>
In the last quarter, Ford sold 177,275 SUVs, marking a drop of 9% from the corresponding period last year. However, SUVs still accounted for about 40% of the company&#8217;s overall sales in the quarter.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41308588/tesla-superchargers-increase-on-the-road-to-spacexs-starbase-despite-global-slowdown-in-deployment" target="_blank" rel="noreferrer noopener">Tesla Superchargers Increase On The Road To SpaceX's Starbase Despite Global Slowdown In Deployment</a></li>
</ul>
Photo courtesy: Ford

Tech

NHTSA Opens Probe Into Nearly 36K Ford Flex Vehicles Over Claims Of Rearview Camera Failure

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) with a Buy and maintains $29 price target.

Price Target

Reiteration

Analyst Ratings

NRIX

Needham Reiterates Buy on Nurix Therapeutics, Maintains $29 Price Target

The automated solution from the BD and Hamilton collaboration standardizes traditionally manual processes and speeds the generation of material for genetic sequencing.
The solution includes the newly released BD&reg;&nbsp;OMICS-One XT WTA Assay and the Hamilton&nbsp;Microlab&nbsp;NGS STAR automated liquid handling platform. Because the NGS STAR is already installed in many laboratories and facilities worldwide, more researchers, processing samples across an array of genomics applications, can easily integrate the new automation-ready BD&reg;&nbsp;assay into existing workflows.

BD Reveals Commercial Launch Of New Robotics Solution That Will Enable Automation

Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced data demonstrating more patients with moderately to severely active&nbsp;Crohn's disease treated with mirikizumab achieved histologic&nbsp;response at Week 52 compared to ustekinumab, regardless of prior biologic experience. VIVID-1 is the first Phase 3 study for any approved or investigational treatment in Crohn's disease to report histologic and combined histologic-endoscopic outcomes that were evaluated using a systematic assessment of five bowel segments (four colonic and one ileal) and strict definitions consistent with the recently published European Crohn's and Colitis (ECCO) position statement on mucosal histopathology. These results are being presented as an oral presentation at United European Gastroenterology (UEG) Week, held in Vienna, Austria from October 12-15.
Mirikizumab is an IL23p19 antagonist that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Inflammation due to the overactivation of the IL-23 pathway plays a critical role in pathogenesis of Crohn's disease, a chronic, inflammatory bowel disease associated with progressive bowel damage, disability and decreased health-related quality of life.
Crohn's disease inflammation occurs at the cellular level—defined as histologic inflammation—and persists even after treatment with standard of care therapies in up to one-quarter of patients with Crohn's disease despite evidence of endoscopic mucosal healing.

Eli Lilly's Mirikizumab Shows Results in Week 52 Crohn's Disease Study Compared to Ustekinumab

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and maintains $205 price target.

SRPT

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $205 Price Target

As Columbus Day approaches, investors and market participants are preparing for a unique trading environment. This U.S. holiday, observed on Monday, October 14, 2024, will see a mix of open and closed financial markets, impacting trading activities.
Columbus Day, a federal holiday commemorating the 1492 landing of Christopher Columbus in North America, will see the New York Stock Exchange and the Nasdaq Stock Market operating as usually. Over-the-counter (OTC) markets will also remain open, while bond markets will be closed. The U.S. Postal Service and the Federal Reserve will not operate, and many banks will follow suit. 
In some states, the day is also recognized as Indigenous People&#8217;s Day, celebrating the resilience of Indigenous communities.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41299648/bitcoin-ethereum-dogecoin-see-friday-gains-but-trader-warns-59-000-must-hold-no-major-move?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin See Friday Gains, But Trader Warns &#8216;$59,000 Must Hold, No Major Moves Expecte</a>
Internationally, trading will continue as usual in most markets, except for the Toronto Stock Exchange, which will close in observance of Canada&#8217;s Thanksgiving Day. 
Investors should brace for a busy week with earnings reports from major companies such as UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), and Taiwan Semiconductor Manufacturing Company Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>). Additionally, key economic data releases, including jobless claims, retail sales, and housing starts, will provide insights into the current state of the economy.
Price Action: On Monday during pre-market hours, at the time of writing, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was trading slight higher, around 0.22% while Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up by 0.32%, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41288392/justin-biebers-2024-crypto-returns-discover-how-much-the-pop-icon-made-on-his-ethereum-inv?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Justin Bieber&#8217;s 2024 Crypto Returns – Discover How Much The Pop Icon Made On His Ethereum Investment!</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

General

Columbus Day: Is Stock Market Open Today?

Needham analyst Mayank Tandon reiterates NCR Voyix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VYX#NYSE">VYX</a>) with a Buy and maintains $20 price target.

Needham Reiterates Buy on NCR Voyix, Maintains $20 Price Target

North America&#39;s largest automaker is joining forces with Barclays to build loyalty and engagement with millions of GM customers

General Motors Partners With Barclays To Launch The GM Rewards Mastercard And The GM Business Mastercard

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Buy and maintains $18 price target.

ADMA

HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Maintains $18 Price Target

Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of $60.00 per share in cash. The transaction is valued at approximately $2.6 billion equity value and USD 2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis.
The board of directors of both companies have unanimously approved the transaction. The transaction is expected to close in the&nbsp;fourth quarter&nbsp;of 2024, subject to the tender of at least a majority of the total number of Longboard outstanding voting shares, receipt of required regulatory clearances, and other customary conditions.
The cash consideration represents a&nbsp;77%&nbsp;premium to the 30-day volume-weighted average price (&quot;VWAP&quot;) of shares of Longboard common stock as of September 30, 2024.
Lundbeck&#39;s financial&nbsp;guidance&nbsp;for 2024 is confirmed.

LBPH

Lundbeck Agrees To Acquire Longboard Pharmaceuticals In Transaction Valued At Approximately $2.6B Equity Value

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) with a Neutral.

HC Wainwright & Co. Reiterates Neutral on Kezar Life Sciences

Biotech

Health Care

H. Lundbeck Has Agreed To Acquire Longboard Pharmaceuticals For $60 Per Share In Cash. The Transaction Is Valued At Approximately $2.6B Equity Value And $2.5B On A Fully Diluted Basis

HC Wainwright &amp; Co. analyst Robert Burns reiterates Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Buy and maintains $19 price target.

RLAY

HC Wainwright & Co. Reiterates Buy on Relay Therapeutics, Maintains $19 Price Target

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) with a Buy and maintains $25 price target.

MIST

HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target

Simultaneously, Redwire has started spacecraft integration for two other ESA satellite missions, the Atmospheric Limb Tracker for Investigation of the Upcoming Stratosphere (ALTIUS) and one of the In-Orbit Demonstration and Verification (Horizon 2020 IOD/IOV) satellites, funded by the European Union, at its state-of-the-art facility in Kruibeke, Belgium.

Redwire Says Finalizing Integration And Preparing For Delivery Of Two Satellites For European Space Agency's Proba-3 Mission Later In Q4 Of This Year

Guidance

ENLT

Enlight Renewable Energy Completes COD Of Its Solar And Storage Cluster In Israel; Expects Cluster To Generate Revenue Of $34M-36M And EBITDA Of $24M-26M In First Full Operating Year

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and maintains $37 price target.

ALKS

HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $37 Price Target

Highwoods Properties Says Its Buildings Have Not Sustained Any Notable Damage From Hurricane Milton

Wedbush analyst Nick Setyan reiterates Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Outperform and maintains $45 price target.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Argentex Group

News

Latest news for Argentex Group (OTC:AGXTF) Stock